International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines
Identifieur interne : 000218 ( PascalFrancis/Corpus ); précédent : 000217; suivant : 000219International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines
Auteurs : Caitlin N. Dodd ; Silvana A. Romio ; Steven Black ; Claudia Vellozzi ; Nick Andrews ; Miriam Sturkenboom ; Patrick Zuber ; WEI HUA ; Jan Bonhoeffer ; Jim Buttery ; Nigel Crawford ; Genevieve Deceuninck ; Corinne De Vries ; Philippe De Wals ; M. Victoria Gutierrez-Gimeno ; Harald Heijbel ; Hayley Hughes ; Kwan Hur ; Anders Hviid ; Jeffrey Kelman ; Tehri Kilpi ; S. K. Chuang ; Kristine Macartney ; Melisa Rett ; Vesta Richardson Lopez-Callada ; Daniel Salmon ; Francisco Gimenez Sanchez ; Nuria Sanz ; Barbara Silverman ; Jann Storsaeter ; Umapathi Thirugnanam ; Nicoline Van Der Maas ; Katherine Yih ; TAO ZHANG ; Hector IzurietaSource :
- Vaccine [ 0264-410X ] ; 2013.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Background: The global spread of the 2009 novel pandemic influenza A (H1N1) virus led to the accelerated production and distribution of monovalent 2009 Influenza A (H1N1) vaccines (pH1N1). This pandemic provided the opportunity to evaluate the risk of Guillain-Barré syndrome (GBS), which has been an influenza vaccine safety concern since the swine flu pandemic of 1976, using a common protocol among high and middle-income countries. The primary objective of this project was to demonstrate the feasibility and utility of global collaboration in the assessment of vaccine safety, including countries both with and without an established infrastructure for vaccine active safety surveillance.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
|
|---|
Format Inist (serveur)
| NO : | PASCAL 13-0324661 INIST |
|---|---|
| ET : | International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines |
| AU : | DODD (Caitlin N.); ROMIO (Silvana A.); BLACK (Steven); VELLOZZI (Claudia); ANDREWS (Nick); STURKENBOOM (Miriam); ZUBER (Patrick); WEI HUA; BONHOEFFER (Jan); BUTTERY (Jim); CRAWFORD (Nigel); DECEUNINCK (Genevieve); DE VRIES (Corinne); DE WALS (Philippe); GUTIERREZ-GIMENO (M. Victoria); HEIJBEL (Harald); HUGHES (Hayley); HUR (Kwan); HVIID (Anders); KELMAN (Jeffrey); KILPI (Tehri); CHUANG (S. K.); MACARTNEY (Kristine); RETT (Melisa); LOPEZ-CALLADA (Vesta Richardson); SALMON (Daniel); GIMENEZ SANCHEZ (Francisco); SANZ (Nuria); SILVERMAN (Barbara); STORSAETER (Jann); THIRUGNANAM (Umapathi); VAN DER MAAS (Nicoline); YIH (Katherine); TAO ZHANG; IZURIETA (Hector) |
| AF : | Department of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center/Cincinnati, OH/Etats-Unis (1 aut.); Department of Medical Informatics, Erasmus University Medical Center/Rotterdam/Pays-Bas (2 aut., 6 aut.); Department of Global Child Health, Cincinnati Children's Hospital Medical Center/Cincinnati, OH/Etats-Unis (3 aut.); Centers for Disease Control and Prevention/Atlanta, GA/Etats-Unis (4 aut.); Health Protection Agency/London/Royaume-Uni (5 aut.); Department of Immunizations, Vaccines and Biologicals (IVB), World Health Organization/Genève/Suisse (7 aut.); Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, Food and Drug Administration/Rockville, MD/Etats-Unis (8 aut., 35 aut.); Brighton Collaboration Foundation/Basel/Suisse (9 aut.); University Children's Hospital/Basel/Suisse (9 aut.); Murdoch Children's Research Institute, Dept of Paediatrics, Monash University/Victoria/Australie (10 aut.); The Department of Paediatrics, University of Melbourne/Melbourne/Australie (11 aut.); Public Health Research Unit, Quebec University Hospital Research Centre/Quebec City, Quebec/Canada (12 aut., 14 aut.); Department of Pharmacy & Pharmacology, University of Bath/Bath/Royaume-Uni (13 aut.); Vaccine Department, Centre of Public Health Research (CSISP-FISABIO)/Valencia/Espagne (15 aut.); Swedish Institute for Infectious Disease Control/Lund/Suède (16 aut.); Department of Defense/Washington, DC/Etats-Unis (17 aut.); Center for Medication Safety, Pharmacy Benefit Management Services, Hines Veterans Affairs Hospital/Hines, IL/Etats-Unis (18 aut.); Department of Epidemiology Research, Statens Serum Institute/Copenhagen/Danemark (19 aut.); Center for Drug and Health Plan Choice, Centers for Medicare and Medicaid Services/Baltimore, MD/Etats-Unis (20 aut.); National Institute for Health and Welfare/Helsinki/Finlande (21 aut.); Centre for Health Protection, Department of Health/Hong-Kong (22 aut.); Children's Hospital at Westmead/Westmead, New South Wales/Australie (23 aut.); Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute/Boston, MA/Etats-Unis (24 aut., 33 aut.); National Center for Child and Adolescent Health/Mexico City, Mexico/Mexique (25 aut.); National Vaccine Program Office, Office of the Assistant Secretary for Health, U.S Department of Health and Human Services/Washington, DC/Etats-Unis (26 aut.) |
| DT : | Publication en série; Niveau analytique |
| SO : | Vaccine; ISSN 0264-410X; Coden VACCDE; Royaume-Uni; Da. 2013; Vol. 31; No. 40; Pp. 4448-4458; Bibl. 46 ref. |
| LA : | Anglais |
| EA : | Background: The global spread of the 2009 novel pandemic influenza A (H1N1) virus led to the accelerated production and distribution of monovalent 2009 Influenza A (H1N1) vaccines (pH1N1). This pandemic provided the opportunity to evaluate the risk of Guillain-Barré syndrome (GBS), which has been an influenza vaccine safety concern since the swine flu pandemic of 1976, using a common protocol among high and middle-income countries. The primary objective of this project was to demonstrate the feasibility and utility of global collaboration in the assessment of vaccine safety, including countries both with and without an established infrastructure for vaccine active safety surveillance. |
| CC : | 002A05F04; 002A05C10 |
| FD : | Virus grippal A; Vaccin; Méthode; Adjuvant immunologique; Toxicité; Immunisation; Polyradiculonévrite de Guillain-Barré; Grippe A; Virus grippal A(H1N1) |
| FG : | Influenzavirus A; Orthomyxoviridae; Virus; Maladie inflammatoire; Virose; Infection; Pathologie du système nerveux périphérique; Pathologie du système nerveux |
| ED : | Influenza A virus; Vaccine; Method; Immunological adjuvant; Toxicity; Immunization; Guillain-Barré syndrome; Influenza A; Influenzavirus A(H1N1) |
| EG : | Influenzavirus A; Orthomyxoviridae; Virus; Inflammatory disease; Viral disease; Infection; Peripheral nerve disease; Nervous system diseases |
| SD : | Influenza A virus; Vacuna; Método; Coadyuvante inmunológico; Toxicidad; Inmunización; Polirradiculoneuritis Guillain-Barré; Gripe A |
| LO : | INIST-20289.354000501976730270 |
| ID : | 13-0324661 |
Links to Exploration step
Pascal:13-0324661Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines</title><author><name sortKey="Dodd, Caitlin N" sort="Dodd, Caitlin N" uniqKey="Dodd C" first="Caitlin N." last="Dodd">Caitlin N. Dodd</name><affiliation><inist:fA14 i1="01"><s1>Department of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center</s1><s2>Cincinnati, OH</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Romio, Silvana A" sort="Romio, Silvana A" uniqKey="Romio S" first="Silvana A." last="Romio">Silvana A. Romio</name><affiliation><inist:fA14 i1="02"><s1>Department of Medical Informatics, Erasmus University Medical Center</s1><s2>Rotterdam</s2><s3>NLD</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Black, Steven" sort="Black, Steven" uniqKey="Black S" first="Steven" last="Black">Steven Black</name><affiliation><inist:fA14 i1="03"><s1>Department of Global Child Health, Cincinnati Children's Hospital Medical Center</s1><s2>Cincinnati, OH</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Vellozzi, Claudia" sort="Vellozzi, Claudia" uniqKey="Vellozzi C" first="Claudia" last="Vellozzi">Claudia Vellozzi</name><affiliation><inist:fA14 i1="04"><s1>Centers for Disease Control and Prevention</s1><s2>Atlanta, GA</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Andrews, Nick" sort="Andrews, Nick" uniqKey="Andrews N" first="Nick" last="Andrews">Nick Andrews</name><affiliation><inist:fA14 i1="05"><s1>Health Protection Agency</s1><s2>London</s2><s3>GBR</s3><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Sturkenboom, Miriam" sort="Sturkenboom, Miriam" uniqKey="Sturkenboom M" first="Miriam" last="Sturkenboom">Miriam Sturkenboom</name><affiliation><inist:fA14 i1="02"><s1>Department of Medical Informatics, Erasmus University Medical Center</s1><s2>Rotterdam</s2><s3>NLD</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Zuber, Patrick" sort="Zuber, Patrick" uniqKey="Zuber P" first="Patrick" last="Zuber">Patrick Zuber</name><affiliation><inist:fA14 i1="06"><s1>Department of Immunizations, Vaccines and Biologicals (IVB), World Health Organization</s1><s2>Genève</s2><s3>CHE</s3><sZ>7 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Wei Hua" sort="Wei Hua" uniqKey="Wei Hua" last="Wei Hua">WEI HUA</name><affiliation><inist:fA14 i1="07"><s1>Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, Food and Drug Administration</s1><s2>Rockville, MD</s2><s3>USA</s3><sZ>8 aut.</sZ><sZ>35 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Bonhoeffer, Jan" sort="Bonhoeffer, Jan" uniqKey="Bonhoeffer J" first="Jan" last="Bonhoeffer">Jan Bonhoeffer</name><affiliation><inist:fA14 i1="08"><s1>Brighton Collaboration Foundation</s1><s2>Basel</s2><s3>CHE</s3><sZ>9 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="09"><s1>University Children's Hospital</s1><s2>Basel</s2><s3>CHE</s3><sZ>9 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Buttery, Jim" sort="Buttery, Jim" uniqKey="Buttery J" first="Jim" last="Buttery">Jim Buttery</name><affiliation><inist:fA14 i1="10"><s1>Murdoch Children's Research Institute, Dept of Paediatrics, Monash University</s1><s2>Victoria</s2><s3>AUS</s3><sZ>10 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Crawford, Nigel" sort="Crawford, Nigel" uniqKey="Crawford N" first="Nigel" last="Crawford">Nigel Crawford</name><affiliation><inist:fA14 i1="11"><s1>The Department of Paediatrics, University of Melbourne</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>11 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Deceuninck, Genevieve" sort="Deceuninck, Genevieve" uniqKey="Deceuninck G" first="Genevieve" last="Deceuninck">Genevieve Deceuninck</name><affiliation><inist:fA14 i1="12"><s1>Public Health Research Unit, Quebec University Hospital Research Centre</s1><s2>Quebec City, Quebec</s2><s3>CAN</s3><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="De Vries, Corinne" sort="De Vries, Corinne" uniqKey="De Vries C" first="Corinne" last="De Vries">Corinne De Vries</name><affiliation><inist:fA14 i1="13"><s1>Department of Pharmacy & Pharmacology, University of Bath</s1><s2>Bath</s2><s3>GBR</s3><sZ>13 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="De Wals, Philippe" sort="De Wals, Philippe" uniqKey="De Wals P" first="Philippe" last="De Wals">Philippe De Wals</name><affiliation><inist:fA14 i1="12"><s1>Public Health Research Unit, Quebec University Hospital Research Centre</s1><s2>Quebec City, Quebec</s2><s3>CAN</s3><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Gutierrez Gimeno, M Victoria" sort="Gutierrez Gimeno, M Victoria" uniqKey="Gutierrez Gimeno M" first="M. Victoria" last="Gutierrez-Gimeno">M. Victoria Gutierrez-Gimeno</name><affiliation><inist:fA14 i1="14"><s1>Vaccine Department, Centre of Public Health Research (CSISP-FISABIO)</s1><s2>Valencia</s2><s3>ESP</s3><sZ>15 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Heijbel, Harald" sort="Heijbel, Harald" uniqKey="Heijbel H" first="Harald" last="Heijbel">Harald Heijbel</name><affiliation><inist:fA14 i1="15"><s1>Swedish Institute for Infectious Disease Control</s1><s2>Lund</s2><s3>SWE</s3><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Hughes, Hayley" sort="Hughes, Hayley" uniqKey="Hughes H" first="Hayley" last="Hughes">Hayley Hughes</name><affiliation><inist:fA14 i1="16"><s1>Department of Defense</s1><s2>Washington, DC</s2><s3>USA</s3><sZ>17 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Hur, Kwan" sort="Hur, Kwan" uniqKey="Hur K" first="Kwan" last="Hur">Kwan Hur</name><affiliation><inist:fA14 i1="17"><s1>Center for Medication Safety, Pharmacy Benefit Management Services, Hines Veterans Affairs Hospital</s1><s2>Hines, IL</s2><s3>USA</s3><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Hviid, Anders" sort="Hviid, Anders" uniqKey="Hviid A" first="Anders" last="Hviid">Anders Hviid</name><affiliation><inist:fA14 i1="18"><s1>Department of Epidemiology Research, Statens Serum Institute</s1><s2>Copenhagen</s2><s3>DNK</s3><sZ>19 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Kelman, Jeffrey" sort="Kelman, Jeffrey" uniqKey="Kelman J" first="Jeffrey" last="Kelman">Jeffrey Kelman</name><affiliation><inist:fA14 i1="19"><s1>Center for Drug and Health Plan Choice, Centers for Medicare and Medicaid Services</s1><s2>Baltimore, MD</s2><s3>USA</s3><sZ>20 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Kilpi, Tehri" sort="Kilpi, Tehri" uniqKey="Kilpi T" first="Tehri" last="Kilpi">Tehri Kilpi</name><affiliation><inist:fA14 i1="20"><s1>National Institute for Health and Welfare</s1><s2>Helsinki</s2><s3>FIN</s3><sZ>21 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Chuang, S K" sort="Chuang, S K" uniqKey="Chuang S" first="S. K." last="Chuang">S. K. Chuang</name><affiliation><inist:fA14 i1="21"><s1>Centre for Health Protection, Department of Health</s1><s3>HKG</s3><sZ>22 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Macartney, Kristine" sort="Macartney, Kristine" uniqKey="Macartney K" first="Kristine" last="Macartney">Kristine Macartney</name><affiliation><inist:fA14 i1="22"><s1>Children's Hospital at Westmead</s1><s2>Westmead, New South Wales</s2><s3>AUS</s3><sZ>23 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Rett, Melisa" sort="Rett, Melisa" uniqKey="Rett M" first="Melisa" last="Rett">Melisa Rett</name><affiliation><inist:fA14 i1="23"><s1>Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>24 aut.</sZ><sZ>33 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Lopez Callada, Vesta Richardson" sort="Lopez Callada, Vesta Richardson" uniqKey="Lopez Callada V" first="Vesta Richardson" last="Lopez-Callada">Vesta Richardson Lopez-Callada</name><affiliation><inist:fA14 i1="24"><s1>National Center for Child and Adolescent Health</s1><s2>Mexico City, Mexico</s2><s3>MEX</s3><sZ>25 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Salmon, Daniel" sort="Salmon, Daniel" uniqKey="Salmon D" first="Daniel" last="Salmon">Daniel Salmon</name><affiliation><inist:fA14 i1="25"><s1>National Vaccine Program Office, Office of the Assistant Secretary for Health, U.S Department of Health and Human Services</s1><s2>Washington, DC</s2><s3>USA</s3><sZ>26 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Gimenez Sanchez, Francisco" sort="Gimenez Sanchez, Francisco" uniqKey="Gimenez Sanchez F" first="Francisco" last="Gimenez Sanchez">Francisco Gimenez Sanchez</name></author><author><name sortKey="Sanz, Nuria" sort="Sanz, Nuria" uniqKey="Sanz N" first="Nuria" last="Sanz">Nuria Sanz</name></author><author><name sortKey="Silverman, Barbara" sort="Silverman, Barbara" uniqKey="Silverman B" first="Barbara" last="Silverman">Barbara Silverman</name></author><author><name sortKey="Storsaeter, Jann" sort="Storsaeter, Jann" uniqKey="Storsaeter J" first="Jann" last="Storsaeter">Jann Storsaeter</name></author><author><name sortKey="Thirugnanam, Umapathi" sort="Thirugnanam, Umapathi" uniqKey="Thirugnanam U" first="Umapathi" last="Thirugnanam">Umapathi Thirugnanam</name></author><author><name sortKey="Van Der Maas, Nicoline" sort="Van Der Maas, Nicoline" uniqKey="Van Der Maas N" first="Nicoline" last="Van Der Maas">Nicoline Van Der Maas</name></author><author><name sortKey="Yih, Katherine" sort="Yih, Katherine" uniqKey="Yih K" first="Katherine" last="Yih">Katherine Yih</name><affiliation><inist:fA14 i1="23"><s1>Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>24 aut.</sZ><sZ>33 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Tao Zhang" sort="Tao Zhang" uniqKey="Tao Zhang" last="Tao Zhang">TAO ZHANG</name></author><author><name sortKey="Izurieta, Hector" sort="Izurieta, Hector" uniqKey="Izurieta H" first="Hector" last="Izurieta">Hector Izurieta</name><affiliation><inist:fA14 i1="07"><s1>Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, Food and Drug Administration</s1><s2>Rockville, MD</s2><s3>USA</s3><sZ>8 aut.</sZ><sZ>35 aut.</sZ></inist:fA14></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">13-0324661</idno><date when="2013">2013</date><idno type="stanalyst">PASCAL 13-0324661 INIST</idno><idno type="RBID">Pascal:13-0324661</idno><idno type="wicri:Area/PascalFrancis/Corpus">000218</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines</title><author><name sortKey="Dodd, Caitlin N" sort="Dodd, Caitlin N" uniqKey="Dodd C" first="Caitlin N." last="Dodd">Caitlin N. Dodd</name><affiliation><inist:fA14 i1="01"><s1>Department of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center</s1><s2>Cincinnati, OH</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Romio, Silvana A" sort="Romio, Silvana A" uniqKey="Romio S" first="Silvana A." last="Romio">Silvana A. Romio</name><affiliation><inist:fA14 i1="02"><s1>Department of Medical Informatics, Erasmus University Medical Center</s1><s2>Rotterdam</s2><s3>NLD</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Black, Steven" sort="Black, Steven" uniqKey="Black S" first="Steven" last="Black">Steven Black</name><affiliation><inist:fA14 i1="03"><s1>Department of Global Child Health, Cincinnati Children's Hospital Medical Center</s1><s2>Cincinnati, OH</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Vellozzi, Claudia" sort="Vellozzi, Claudia" uniqKey="Vellozzi C" first="Claudia" last="Vellozzi">Claudia Vellozzi</name><affiliation><inist:fA14 i1="04"><s1>Centers for Disease Control and Prevention</s1><s2>Atlanta, GA</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Andrews, Nick" sort="Andrews, Nick" uniqKey="Andrews N" first="Nick" last="Andrews">Nick Andrews</name><affiliation><inist:fA14 i1="05"><s1>Health Protection Agency</s1><s2>London</s2><s3>GBR</s3><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Sturkenboom, Miriam" sort="Sturkenboom, Miriam" uniqKey="Sturkenboom M" first="Miriam" last="Sturkenboom">Miriam Sturkenboom</name><affiliation><inist:fA14 i1="02"><s1>Department of Medical Informatics, Erasmus University Medical Center</s1><s2>Rotterdam</s2><s3>NLD</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Zuber, Patrick" sort="Zuber, Patrick" uniqKey="Zuber P" first="Patrick" last="Zuber">Patrick Zuber</name><affiliation><inist:fA14 i1="06"><s1>Department of Immunizations, Vaccines and Biologicals (IVB), World Health Organization</s1><s2>Genève</s2><s3>CHE</s3><sZ>7 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Wei Hua" sort="Wei Hua" uniqKey="Wei Hua" last="Wei Hua">WEI HUA</name><affiliation><inist:fA14 i1="07"><s1>Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, Food and Drug Administration</s1><s2>Rockville, MD</s2><s3>USA</s3><sZ>8 aut.</sZ><sZ>35 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Bonhoeffer, Jan" sort="Bonhoeffer, Jan" uniqKey="Bonhoeffer J" first="Jan" last="Bonhoeffer">Jan Bonhoeffer</name><affiliation><inist:fA14 i1="08"><s1>Brighton Collaboration Foundation</s1><s2>Basel</s2><s3>CHE</s3><sZ>9 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="09"><s1>University Children's Hospital</s1><s2>Basel</s2><s3>CHE</s3><sZ>9 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Buttery, Jim" sort="Buttery, Jim" uniqKey="Buttery J" first="Jim" last="Buttery">Jim Buttery</name><affiliation><inist:fA14 i1="10"><s1>Murdoch Children's Research Institute, Dept of Paediatrics, Monash University</s1><s2>Victoria</s2><s3>AUS</s3><sZ>10 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Crawford, Nigel" sort="Crawford, Nigel" uniqKey="Crawford N" first="Nigel" last="Crawford">Nigel Crawford</name><affiliation><inist:fA14 i1="11"><s1>The Department of Paediatrics, University of Melbourne</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>11 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Deceuninck, Genevieve" sort="Deceuninck, Genevieve" uniqKey="Deceuninck G" first="Genevieve" last="Deceuninck">Genevieve Deceuninck</name><affiliation><inist:fA14 i1="12"><s1>Public Health Research Unit, Quebec University Hospital Research Centre</s1><s2>Quebec City, Quebec</s2><s3>CAN</s3><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="De Vries, Corinne" sort="De Vries, Corinne" uniqKey="De Vries C" first="Corinne" last="De Vries">Corinne De Vries</name><affiliation><inist:fA14 i1="13"><s1>Department of Pharmacy & Pharmacology, University of Bath</s1><s2>Bath</s2><s3>GBR</s3><sZ>13 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="De Wals, Philippe" sort="De Wals, Philippe" uniqKey="De Wals P" first="Philippe" last="De Wals">Philippe De Wals</name><affiliation><inist:fA14 i1="12"><s1>Public Health Research Unit, Quebec University Hospital Research Centre</s1><s2>Quebec City, Quebec</s2><s3>CAN</s3><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Gutierrez Gimeno, M Victoria" sort="Gutierrez Gimeno, M Victoria" uniqKey="Gutierrez Gimeno M" first="M. Victoria" last="Gutierrez-Gimeno">M. Victoria Gutierrez-Gimeno</name><affiliation><inist:fA14 i1="14"><s1>Vaccine Department, Centre of Public Health Research (CSISP-FISABIO)</s1><s2>Valencia</s2><s3>ESP</s3><sZ>15 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Heijbel, Harald" sort="Heijbel, Harald" uniqKey="Heijbel H" first="Harald" last="Heijbel">Harald Heijbel</name><affiliation><inist:fA14 i1="15"><s1>Swedish Institute for Infectious Disease Control</s1><s2>Lund</s2><s3>SWE</s3><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Hughes, Hayley" sort="Hughes, Hayley" uniqKey="Hughes H" first="Hayley" last="Hughes">Hayley Hughes</name><affiliation><inist:fA14 i1="16"><s1>Department of Defense</s1><s2>Washington, DC</s2><s3>USA</s3><sZ>17 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Hur, Kwan" sort="Hur, Kwan" uniqKey="Hur K" first="Kwan" last="Hur">Kwan Hur</name><affiliation><inist:fA14 i1="17"><s1>Center for Medication Safety, Pharmacy Benefit Management Services, Hines Veterans Affairs Hospital</s1><s2>Hines, IL</s2><s3>USA</s3><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Hviid, Anders" sort="Hviid, Anders" uniqKey="Hviid A" first="Anders" last="Hviid">Anders Hviid</name><affiliation><inist:fA14 i1="18"><s1>Department of Epidemiology Research, Statens Serum Institute</s1><s2>Copenhagen</s2><s3>DNK</s3><sZ>19 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Kelman, Jeffrey" sort="Kelman, Jeffrey" uniqKey="Kelman J" first="Jeffrey" last="Kelman">Jeffrey Kelman</name><affiliation><inist:fA14 i1="19"><s1>Center for Drug and Health Plan Choice, Centers for Medicare and Medicaid Services</s1><s2>Baltimore, MD</s2><s3>USA</s3><sZ>20 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Kilpi, Tehri" sort="Kilpi, Tehri" uniqKey="Kilpi T" first="Tehri" last="Kilpi">Tehri Kilpi</name><affiliation><inist:fA14 i1="20"><s1>National Institute for Health and Welfare</s1><s2>Helsinki</s2><s3>FIN</s3><sZ>21 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Chuang, S K" sort="Chuang, S K" uniqKey="Chuang S" first="S. K." last="Chuang">S. K. Chuang</name><affiliation><inist:fA14 i1="21"><s1>Centre for Health Protection, Department of Health</s1><s3>HKG</s3><sZ>22 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Macartney, Kristine" sort="Macartney, Kristine" uniqKey="Macartney K" first="Kristine" last="Macartney">Kristine Macartney</name><affiliation><inist:fA14 i1="22"><s1>Children's Hospital at Westmead</s1><s2>Westmead, New South Wales</s2><s3>AUS</s3><sZ>23 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Rett, Melisa" sort="Rett, Melisa" uniqKey="Rett M" first="Melisa" last="Rett">Melisa Rett</name><affiliation><inist:fA14 i1="23"><s1>Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>24 aut.</sZ><sZ>33 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Lopez Callada, Vesta Richardson" sort="Lopez Callada, Vesta Richardson" uniqKey="Lopez Callada V" first="Vesta Richardson" last="Lopez-Callada">Vesta Richardson Lopez-Callada</name><affiliation><inist:fA14 i1="24"><s1>National Center for Child and Adolescent Health</s1><s2>Mexico City, Mexico</s2><s3>MEX</s3><sZ>25 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Salmon, Daniel" sort="Salmon, Daniel" uniqKey="Salmon D" first="Daniel" last="Salmon">Daniel Salmon</name><affiliation><inist:fA14 i1="25"><s1>National Vaccine Program Office, Office of the Assistant Secretary for Health, U.S Department of Health and Human Services</s1><s2>Washington, DC</s2><s3>USA</s3><sZ>26 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Gimenez Sanchez, Francisco" sort="Gimenez Sanchez, Francisco" uniqKey="Gimenez Sanchez F" first="Francisco" last="Gimenez Sanchez">Francisco Gimenez Sanchez</name></author><author><name sortKey="Sanz, Nuria" sort="Sanz, Nuria" uniqKey="Sanz N" first="Nuria" last="Sanz">Nuria Sanz</name></author><author><name sortKey="Silverman, Barbara" sort="Silverman, Barbara" uniqKey="Silverman B" first="Barbara" last="Silverman">Barbara Silverman</name></author><author><name sortKey="Storsaeter, Jann" sort="Storsaeter, Jann" uniqKey="Storsaeter J" first="Jann" last="Storsaeter">Jann Storsaeter</name></author><author><name sortKey="Thirugnanam, Umapathi" sort="Thirugnanam, Umapathi" uniqKey="Thirugnanam U" first="Umapathi" last="Thirugnanam">Umapathi Thirugnanam</name></author><author><name sortKey="Van Der Maas, Nicoline" sort="Van Der Maas, Nicoline" uniqKey="Van Der Maas N" first="Nicoline" last="Van Der Maas">Nicoline Van Der Maas</name></author><author><name sortKey="Yih, Katherine" sort="Yih, Katherine" uniqKey="Yih K" first="Katherine" last="Yih">Katherine Yih</name><affiliation><inist:fA14 i1="23"><s1>Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>24 aut.</sZ><sZ>33 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Tao Zhang" sort="Tao Zhang" uniqKey="Tao Zhang" last="Tao Zhang">TAO ZHANG</name></author><author><name sortKey="Izurieta, Hector" sort="Izurieta, Hector" uniqKey="Izurieta H" first="Hector" last="Izurieta">Hector Izurieta</name><affiliation><inist:fA14 i1="07"><s1>Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, Food and Drug Administration</s1><s2>Rockville, MD</s2><s3>USA</s3><sZ>8 aut.</sZ><sZ>35 aut.</sZ></inist:fA14></affiliation></author></analytic><series><title level="j" type="main">Vaccine</title><title level="j" type="abbreviated">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Vaccine</title><title level="j" type="abbreviated">Vaccine</title><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Guillain-Barré syndrome</term><term>Immunization</term><term>Immunological adjuvant</term><term>Influenza A</term><term>Influenza A virus</term><term>Influenzavirus A(H1N1)</term><term>Method</term><term>Toxicity</term><term>Vaccine</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Virus grippal A</term><term>Vaccin</term><term>Méthode</term><term>Adjuvant immunologique</term><term>Toxicité</term><term>Immunisation</term><term>Polyradiculonévrite de Guillain-Barré</term><term>Grippe A</term><term>Virus grippal A(H1N1)</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: The global spread of the 2009 novel pandemic influenza A (H1N1) virus led to the accelerated production and distribution of monovalent 2009 Influenza A (H1N1) vaccines (pH1N1). This pandemic provided the opportunity to evaluate the risk of Guillain-Barré syndrome (GBS), which has been an influenza vaccine safety concern since the swine flu pandemic of 1976, using a common protocol among high and middle-income countries. The primary objective of this project was to demonstrate the feasibility and utility of global collaboration in the assessment of vaccine safety, including countries both with and without an established infrastructure for vaccine active safety surveillance.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0264-410X</s0></fA01><fA02 i1="01"><s0>VACCDE</s0></fA02><fA03 i2="1"><s0>Vaccine</s0></fA03><fA05><s2>31</s2></fA05><fA06><s2>40</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines</s1></fA08><fA11 i1="01" i2="1"><s1>DODD (Caitlin N.)</s1></fA11><fA11 i1="02" i2="1"><s1>ROMIO (Silvana A.)</s1></fA11><fA11 i1="03" i2="1"><s1>BLACK (Steven)</s1></fA11><fA11 i1="04" i2="1"><s1>VELLOZZI (Claudia)</s1></fA11><fA11 i1="05" i2="1"><s1>ANDREWS (Nick)</s1></fA11><fA11 i1="06" i2="1"><s1>STURKENBOOM (Miriam)</s1></fA11><fA11 i1="07" i2="1"><s1>ZUBER (Patrick)</s1></fA11><fA11 i1="08" i2="1"><s1>WEI HUA</s1></fA11><fA11 i1="09" i2="1"><s1>BONHOEFFER (Jan)</s1></fA11><fA11 i1="10" i2="1"><s1>BUTTERY (Jim)</s1></fA11><fA11 i1="11" i2="1"><s1>CRAWFORD (Nigel)</s1></fA11><fA11 i1="12" i2="1"><s1>DECEUNINCK (Genevieve)</s1></fA11><fA11 i1="13" i2="1"><s1>DE VRIES (Corinne)</s1></fA11><fA11 i1="14" i2="1"><s1>DE WALS (Philippe)</s1></fA11><fA11 i1="15" i2="1"><s1>GUTIERREZ-GIMENO (M. Victoria)</s1></fA11><fA11 i1="16" i2="1"><s1>HEIJBEL (Harald)</s1></fA11><fA11 i1="17" i2="1"><s1>HUGHES (Hayley)</s1></fA11><fA11 i1="18" i2="1"><s1>HUR (Kwan)</s1></fA11><fA11 i1="19" i2="1"><s1>HVIID (Anders)</s1></fA11><fA11 i1="20" i2="1"><s1>KELMAN (Jeffrey)</s1></fA11><fA11 i1="21" i2="1"><s1>KILPI (Tehri)</s1></fA11><fA11 i1="22" i2="1"><s1>CHUANG (S. K.)</s1></fA11><fA11 i1="23" i2="1"><s1>MACARTNEY (Kristine)</s1></fA11><fA11 i1="24" i2="1"><s1>RETT (Melisa)</s1></fA11><fA11 i1="25" i2="1"><s1>LOPEZ-CALLADA (Vesta Richardson)</s1></fA11><fA11 i1="26" i2="1"><s1>SALMON (Daniel)</s1></fA11><fA11 i1="27" i2="1"><s1>GIMENEZ SANCHEZ (Francisco)</s1></fA11><fA11 i1="28" i2="1"><s1>SANZ (Nuria)</s1></fA11><fA11 i1="29" i2="1"><s1>SILVERMAN (Barbara)</s1></fA11><fA11 i1="30" i2="1"><s1>STORSAETER (Jann)</s1></fA11><fA11 i1="31" i2="1"><s1>THIRUGNANAM (Umapathi)</s1></fA11><fA11 i1="32" i2="1"><s1>VAN DER MAAS (Nicoline)</s1></fA11><fA11 i1="33" i2="1"><s1>YIH (Katherine)</s1></fA11><fA11 i1="34" i2="1"><s1>TAO ZHANG</s1></fA11><fA11 i1="35" i2="1"><s1>IZURIETA (Hector)</s1></fA11><fA14 i1="01"><s1>Department of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center</s1><s2>Cincinnati, OH</s2><s3>USA</s3><sZ>1 aut.</sZ></fA14><fA14 i1="02"><s1>Department of Medical Informatics, Erasmus University Medical Center</s1><s2>Rotterdam</s2><s3>NLD</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ></fA14><fA14 i1="03"><s1>Department of Global Child Health, Cincinnati Children's Hospital Medical Center</s1><s2>Cincinnati, OH</s2><s3>USA</s3><sZ>3 aut.</sZ></fA14><fA14 i1="04"><s1>Centers for Disease Control and Prevention</s1><s2>Atlanta, GA</s2><s3>USA</s3><sZ>4 aut.</sZ></fA14><fA14 i1="05"><s1>Health Protection Agency</s1><s2>London</s2><s3>GBR</s3><sZ>5 aut.</sZ></fA14><fA14 i1="06"><s1>Department of Immunizations, Vaccines and Biologicals (IVB), World Health Organization</s1><s2>Genève</s2><s3>CHE</s3><sZ>7 aut.</sZ></fA14><fA14 i1="07"><s1>Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, Food and Drug Administration</s1><s2>Rockville, MD</s2><s3>USA</s3><sZ>8 aut.</sZ><sZ>35 aut.</sZ></fA14><fA14 i1="08"><s1>Brighton Collaboration Foundation</s1><s2>Basel</s2><s3>CHE</s3><sZ>9 aut.</sZ></fA14><fA14 i1="09"><s1>University Children's Hospital</s1><s2>Basel</s2><s3>CHE</s3><sZ>9 aut.</sZ></fA14><fA14 i1="10"><s1>Murdoch Children's Research Institute, Dept of Paediatrics, Monash University</s1><s2>Victoria</s2><s3>AUS</s3><sZ>10 aut.</sZ></fA14><fA14 i1="11"><s1>The Department of Paediatrics, University of Melbourne</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>11 aut.</sZ></fA14><fA14 i1="12"><s1>Public Health Research Unit, Quebec University Hospital Research Centre</s1><s2>Quebec City, Quebec</s2><s3>CAN</s3><sZ>12 aut.</sZ><sZ>14 aut.</sZ></fA14><fA14 i1="13"><s1>Department of Pharmacy & Pharmacology, University of Bath</s1><s2>Bath</s2><s3>GBR</s3><sZ>13 aut.</sZ></fA14><fA14 i1="14"><s1>Vaccine Department, Centre of Public Health Research (CSISP-FISABIO)</s1><s2>Valencia</s2><s3>ESP</s3><sZ>15 aut.</sZ></fA14><fA14 i1="15"><s1>Swedish Institute for Infectious Disease Control</s1><s2>Lund</s2><s3>SWE</s3><sZ>16 aut.</sZ></fA14><fA14 i1="16"><s1>Department of Defense</s1><s2>Washington, DC</s2><s3>USA</s3><sZ>17 aut.</sZ></fA14><fA14 i1="17"><s1>Center for Medication Safety, Pharmacy Benefit Management Services, Hines Veterans Affairs Hospital</s1><s2>Hines, IL</s2><s3>USA</s3><sZ>18 aut.</sZ></fA14><fA14 i1="18"><s1>Department of Epidemiology Research, Statens Serum Institute</s1><s2>Copenhagen</s2><s3>DNK</s3><sZ>19 aut.</sZ></fA14><fA14 i1="19"><s1>Center for Drug and Health Plan Choice, Centers for Medicare and Medicaid Services</s1><s2>Baltimore, MD</s2><s3>USA</s3><sZ>20 aut.</sZ></fA14><fA14 i1="20"><s1>National Institute for Health and Welfare</s1><s2>Helsinki</s2><s3>FIN</s3><sZ>21 aut.</sZ></fA14><fA14 i1="21"><s1>Centre for Health Protection, Department of Health</s1><s3>HKG</s3><sZ>22 aut.</sZ></fA14><fA14 i1="22"><s1>Children's Hospital at Westmead</s1><s2>Westmead, New South Wales</s2><s3>AUS</s3><sZ>23 aut.</sZ></fA14><fA14 i1="23"><s1>Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>24 aut.</sZ><sZ>33 aut.</sZ></fA14><fA14 i1="24"><s1>National Center for Child and Adolescent Health</s1><s2>Mexico City, Mexico</s2><s3>MEX</s3><sZ>25 aut.</sZ></fA14><fA14 i1="25"><s1>National Vaccine Program Office, Office of the Assistant Secretary for Health, U.S Department of Health and Human Services</s1><s2>Washington, DC</s2><s3>USA</s3><sZ>26 aut.</sZ></fA14><fA17 i1="01" i2="1"><s1>Global H1N1 GBS Consortium</s1><s3>INC</s3></fA17><fA20><s1>4448-4458</s1></fA20><fA21><s1>2013</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20289</s2><s5>354000501976730270</s5></fA43><fA44><s0>0000</s0><s1>© 2013 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>46 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>13-0324661</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Vaccine</s0></fA64><fA66 i1="01"><s0>GBR</s0></fA66><fC01 i1="01" l="ENG"><s0>Background: The global spread of the 2009 novel pandemic influenza A (H1N1) virus led to the accelerated production and distribution of monovalent 2009 Influenza A (H1N1) vaccines (pH1N1). This pandemic provided the opportunity to evaluate the risk of Guillain-Barré syndrome (GBS), which has been an influenza vaccine safety concern since the swine flu pandemic of 1976, using a common protocol among high and middle-income countries. The primary objective of this project was to demonstrate the feasibility and utility of global collaboration in the assessment of vaccine safety, including countries both with and without an established infrastructure for vaccine active safety surveillance.</s0></fC01><fC02 i1="01" i2="X"><s0>002A05F04</s0></fC02><fC02 i1="02" i2="X"><s0>002A05C10</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Virus grippal A</s0><s2>NW</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Influenza A virus</s0><s2>NW</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Influenza A virus</s0><s2>NW</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Vaccin</s0><s5>05</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Vaccine</s0><s5>05</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Vacuna</s0><s5>05</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Méthode</s0><s5>06</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Method</s0><s5>06</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Método</s0><s5>06</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Adjuvant immunologique</s0><s5>07</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Immunological adjuvant</s0><s5>07</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Coadyuvante inmunológico</s0><s5>07</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Toxicité</s0><s5>08</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Toxicity</s0><s5>08</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Toxicidad</s0><s5>08</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Immunisation</s0><s5>09</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Immunization</s0><s5>09</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Inmunización</s0><s5>09</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Polyradiculonévrite de Guillain-Barré</s0><s5>14</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Guillain-Barré syndrome</s0><s5>14</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Polirradiculoneuritis Guillain-Barré</s0><s5>14</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Grippe A</s0><s5>15</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Influenza A</s0><s5>15</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Gripe A</s0><s5>15</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Virus grippal A(H1N1)</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Influenzavirus A(H1N1)</s0><s4>CD</s4><s5>96</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Influenzavirus A</s0><s2>NW</s2></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Influenzavirus A</s0><s2>NW</s2></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Influenzavirus A</s0><s2>NW</s2></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Orthomyxoviridae</s0><s2>NW</s2></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Orthomyxoviridae</s0><s2>NW</s2></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Orthomyxoviridae</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Maladie inflammatoire</s0><s5>13</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Inflammatory disease</s0><s5>13</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad inflamatoria</s0><s5>13</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Virose</s0></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Viral disease</s0></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Virosis</s0></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Infection</s0></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Infection</s0></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Infección</s0></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Pathologie du système nerveux périphérique</s0><s5>16</s5></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Peripheral nerve disease</s0><s5>16</s5></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Nervio periférico patología</s0><s5>16</s5></fC07><fC07 i1="08" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0><s5>17</s5></fC07><fC07 i1="08" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>17</s5></fC07><fC07 i1="08" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>17</s5></fC07><fN21><s1>301</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard><server><NO>PASCAL 13-0324661 INIST</NO><ET>International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines</ET><AU>DODD (Caitlin N.); ROMIO (Silvana A.); BLACK (Steven); VELLOZZI (Claudia); ANDREWS (Nick); STURKENBOOM (Miriam); ZUBER (Patrick); WEI HUA; BONHOEFFER (Jan); BUTTERY (Jim); CRAWFORD (Nigel); DECEUNINCK (Genevieve); DE VRIES (Corinne); DE WALS (Philippe); GUTIERREZ-GIMENO (M. Victoria); HEIJBEL (Harald); HUGHES (Hayley); HUR (Kwan); HVIID (Anders); KELMAN (Jeffrey); KILPI (Tehri); CHUANG (S. K.); MACARTNEY (Kristine); RETT (Melisa); LOPEZ-CALLADA (Vesta Richardson); SALMON (Daniel); GIMENEZ SANCHEZ (Francisco); SANZ (Nuria); SILVERMAN (Barbara); STORSAETER (Jann); THIRUGNANAM (Umapathi); VAN DER MAAS (Nicoline); YIH (Katherine); TAO ZHANG; IZURIETA (Hector)</AU><AF>Department of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center/Cincinnati, OH/Etats-Unis (1 aut.); Department of Medical Informatics, Erasmus University Medical Center/Rotterdam/Pays-Bas (2 aut., 6 aut.); Department of Global Child Health, Cincinnati Children's Hospital Medical Center/Cincinnati, OH/Etats-Unis (3 aut.); Centers for Disease Control and Prevention/Atlanta, GA/Etats-Unis (4 aut.); Health Protection Agency/London/Royaume-Uni (5 aut.); Department of Immunizations, Vaccines and Biologicals (IVB), World Health Organization/Genève/Suisse (7 aut.); Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, Food and Drug Administration/Rockville, MD/Etats-Unis (8 aut., 35 aut.); Brighton Collaboration Foundation/Basel/Suisse (9 aut.); University Children's Hospital/Basel/Suisse (9 aut.); Murdoch Children's Research Institute, Dept of Paediatrics, Monash University/Victoria/Australie (10 aut.); The Department of Paediatrics, University of Melbourne/Melbourne/Australie (11 aut.); Public Health Research Unit, Quebec University Hospital Research Centre/Quebec City, Quebec/Canada (12 aut., 14 aut.); Department of Pharmacy & Pharmacology, University of Bath/Bath/Royaume-Uni (13 aut.); Vaccine Department, Centre of Public Health Research (CSISP-FISABIO)/Valencia/Espagne (15 aut.); Swedish Institute for Infectious Disease Control/Lund/Suède (16 aut.); Department of Defense/Washington, DC/Etats-Unis (17 aut.); Center for Medication Safety, Pharmacy Benefit Management Services, Hines Veterans Affairs Hospital/Hines, IL/Etats-Unis (18 aut.); Department of Epidemiology Research, Statens Serum Institute/Copenhagen/Danemark (19 aut.); Center for Drug and Health Plan Choice, Centers for Medicare and Medicaid Services/Baltimore, MD/Etats-Unis (20 aut.); National Institute for Health and Welfare/Helsinki/Finlande (21 aut.); Centre for Health Protection, Department of Health/Hong-Kong (22 aut.); Children's Hospital at Westmead/Westmead, New South Wales/Australie (23 aut.); Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute/Boston, MA/Etats-Unis (24 aut., 33 aut.); National Center for Child and Adolescent Health/Mexico City, Mexico/Mexique (25 aut.); National Vaccine Program Office, Office of the Assistant Secretary for Health, U.S Department of Health and Human Services/Washington, DC/Etats-Unis (26 aut.)</AF><DT>Publication en série; Niveau analytique</DT><SO>Vaccine; ISSN 0264-410X; Coden VACCDE; Royaume-Uni; Da. 2013; Vol. 31; No. 40; Pp. 4448-4458; Bibl. 46 ref.</SO><LA>Anglais</LA><EA>Background: The global spread of the 2009 novel pandemic influenza A (H1N1) virus led to the accelerated production and distribution of monovalent 2009 Influenza A (H1N1) vaccines (pH1N1). This pandemic provided the opportunity to evaluate the risk of Guillain-Barré syndrome (GBS), which has been an influenza vaccine safety concern since the swine flu pandemic of 1976, using a common protocol among high and middle-income countries. The primary objective of this project was to demonstrate the feasibility and utility of global collaboration in the assessment of vaccine safety, including countries both with and without an established infrastructure for vaccine active safety surveillance.</EA><CC>002A05F04; 002A05C10</CC><FD>Virus grippal A; Vaccin; Méthode; Adjuvant immunologique; Toxicité; Immunisation; Polyradiculonévrite de Guillain-Barré; Grippe A; Virus grippal A(H1N1)</FD><FG>Influenzavirus A; Orthomyxoviridae; Virus; Maladie inflammatoire; Virose; Infection; Pathologie du système nerveux périphérique; Pathologie du système nerveux</FG><ED>Influenza A virus; Vaccine; Method; Immunological adjuvant; Toxicity; Immunization; Guillain-Barré syndrome; Influenza A; Influenzavirus A(H1N1)</ED><EG>Influenzavirus A; Orthomyxoviridae; Virus; Inflammatory disease; Viral disease; Infection; Peripheral nerve disease; Nervous system diseases</EG><SD>Influenza A virus; Vacuna; Método; Coadyuvante inmunológico; Toxicidad; Inmunización; Polirradiculoneuritis Guillain-Barré; Gripe A</SD><LO>INIST-20289.354000501976730270</LO><ID>13-0324661</ID></server></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000218 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000218 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:13-0324661
|texte= International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines
}}
| This area was generated with Dilib version V0.6.34. |  |